Early access
Sign in
Taking people in BelgiumPhase 1

Tests a radioactive drug in adults with advanced colorectal, breast, lung or pancreatic cancer

Tests a radioactive drug, Lu-NNS309, in adults with advanced cancers.

Key facts

Who runs it
Novartis Pharma AG
Where
Anderlecht, BelgiumSee the siteAlso in 5 other countries, 15 sites
Trial code
Registry title
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
Status
Recruiting
Phase
Phase 1
People taking part
76 people, planned
Started
18 Jul 2025
Expected to end
26 Jun 2030
Type of study
Interventional
Record updated
12 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced pancreatic, lung, breast or colorectal cancer that cannot be removed by surgery. It tests the safety and early effect of [177Lu]Lu-NNS309.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Locally advanced and cannot be removed by surgery, or metastatic: pancreatic ductal adenocarcinoma, non-small cell lung cancer, breast cancer or colorectal cancer.

Where in Belgium

Also in 5 other countries, 15 sites

  • Institut Jules BordetAnderlecht, BelgiumTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests a radioactive drug in adults with advanced colorectal, breast, lung or pancreatic cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
12 May 2026